ImmunoGen, Inc. Announces Data Presentations at Upcoming 57th ASH Annual Meeting and Exposition

WALTHAM, Mass.--()--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of new preclinical data with the Company’s experimental therapies IMGN529 and IMGN779 to be made at the upcoming American Society of Hematology (ASH) annual meeting to be held December 5-8, 2015 in Orlando, FL.

“ImmunoGen is advancing experimental therapies expected to make a meaningful difference for patients with cancer, and we believe the preclinical data being presented at ASH with our IMGN529 and IMGN779 help demonstrate the potential significance of these programs”

“ImmunoGen is advancing experimental therapies expected to make a meaningful difference for patients with cancer, and we believe the preclinical data being presented at ASH with our IMGN529 and IMGN779 help demonstrate the potential significance of these programs,” said Dr. Charles Morris, Executive Vice President and Chief Development Officer. “In preclinical assessments, IMGN529 demonstrates marked synergy with rituximab – a widely used therapy for non-Hodgkin lymphoma – which informed our decision to assess this combination clinically. The IMGN779 data being reported relate to its novel mechanism of action, which we believe could help patients with acute myeloid leukemia, and we expect to start clinical testing of this experimental therapy in early 2016.”

In addition to these data presentations on ImmunoGen’s wholly owned compounds, clinical data will be presented with Sanofi’s CD38-targeting antibody isatuximab (SAR650984), which was developed in a research collaboration with ImmunoGen.

Title: “IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergystic Activity with Rituximab in Non-Hodgkin Lymphona (NHL) Models”

  • Poster session #625: Saturday, Dec. 5, 5:30-7:30 pm ET. Abstract #1548.

Title: “IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells”

  • Poster session #616: Saturday, Dec. 5, 5:30-7:30 pm ET. Abstract #1366.

Title: “A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma”

  • Oral presentation #653: Mon., Dec. 7, 8:00 am. Abstract #509.

Additional information can be found at www.hematology.org, including abstracts.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (ADC) technology. The Company’s lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen’s ADC technology to develop novel anticancer therapies; it is used in Roche’s marketed product, Kadcyla®. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN529, IMGN779, and isatuximab (SAR650984), including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015 and other reports filed with the Securities and Exchange Commission.

Contacts

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com

Recent Stories

RSS feed for ImmunoGen, Inc.

ImmunoGen, Inc.